Cargando…
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
BACKGROUND: Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM). RESULTS: The PKIS of 357 compounds was initially evaluated in 15 different GSC lines which then led...
Autores principales: | Dong, Jianwen, Park, Soon Young, Nguyen, Nghi, Ezhilarasan, Ravesanker, Martinez-Ledesma, Emmanuel, Wu, Shaofang, Henry, Verlene, Piao, Yuji, Tiao, Ningyi, Brunell, David, Stephan, Clifford, Verhaak, Roel, Sulman, Erik, Balasubramaniyan, Veerakumar, de Groot, John F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828226/ https://www.ncbi.nlm.nih.gov/pubmed/29535822 http://dx.doi.org/10.18632/oncotarget.24041 |
Ejemplares similares
-
Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma
por: Piao, Yuji, et al.
Publicado: (2017) -
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy
por: Liang, Ji, et al.
Publicado: (2015) -
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015) -
Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2015) -
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2017)